Explore Solstice Oncology careers and hiring status. Find jobs at Solstice Oncology and official application links when roles are open. Funding stage: Series A. Headcount: 11-50. Solstice Oncology is a Boston-based, clinical-stage immuno-oncology company developing porustobart, a next-generation Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed. Its lead program combines porustobart with anti-PD-1 therapy in the neoadjuvant setting for MSS stage II-III colon cancer, with a Phase 2 program underway.
This page summarizes open roles, company profile signals, and official application paths so candidates can quickly evaluate fit before applying. Use the role list below to identify team focus, review location patterns, and jump to source listings. For broader comparison across the market, continue to the full company directory and jobs explorer.
Solstice Oncology is a Series A stage AI startup, founded in 2026, with $225M in total disclosed funding. Its most recent round was a $225M Series A in Sep 2026. It has no open roles listed at the moment; new Solstice Oncology openings are tracked daily. Source: Fast AI Jobs company dataset, updated Sep 2026.
Company profile last updated on Sep 12, 2026.
Solstice Oncology careers and hiring status: no open roles are currently listed here, but you can review the company profile and check the official career page for the latest openings. Official careers page
Solstice Oncology is an biotech company. Solstice Oncology is a Boston-based, clinical-stage immuno-oncology company developing porustobart, a next-generation Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed. Its lead program combines porustobart with anti-PD-1 therapy in the neoadjuvant setting for MSS stage II-III colon cancer, with a Phase 2 program underway.
Open positions
Check the official career page, browse adjacent companies, or subscribe for new openings.
Candidate questions
Solstice Oncology is a Boston-based, clinical-stage immuno-oncology company developing porustobart, a next-generation Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed. Its lead program combines porustobart with anti-PD-1 therapy in the neoadjuvant setting for MSS stage II-III colon cancer, with a Phase 2 program underway.
Solstice Oncology does not have open roles listed on our platform right now. Visit the official company website or career page for the latest openings, or subscribe to get notified when new roles are posted.
Solstice Oncology has raised $225M in total. The latest known stage is Series A.
Solstice Oncology reports an employee count of 11-50.
Solstice Oncology was founded in 2026.
Solstice Oncology is associated with Biotech, Healthcare.
Company context
Solstice Oncology is a Series A stage AI startup, founded in 2026, with $225M in total disclosed funding. Its most recent round was a $225M Series A in Sep 2026. It has no open roles listed at the moment; new Solstice Oncology openings are tracked daily. Source: Fast AI Jobs company dataset, updated Sep 2026.